Microbio Group (TPEx :  4128 ) announced this ( 21 ) evening that its subsidiary Oneness Biotech and Microbio Shanghai, its subsidiary in China, have developed the world's first and only broad-spectrum Covid drug SNS812 . 

The published experimental data shows that the new small nucleic acid drug SNS812 directly locks the important and non-mutable gene region of the new coronavirus through its unique small nucleic acid mechanism, and cuts and destroys the virus gene from the root. It has been confirmed effectively inhibit 99.8% of the mutant strains.

SNS812 is a board-spectrum nucleic acid that has both therapeutic and preventive effects, and it has shown significant inhibitory effects on various coronavirus currently undergoing CMO drug synthesis and CRO animal toxicology experiments, and is expected to submit a US IND application in the middle of this year .